Patents by Inventor Jeremy Bartos

Jeremy Bartos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene
    Patent number: 10039725
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 7, 2018
    Assignees: ChromaDex Inc., The Regents of the Unviersity of California
    Inventors: Jeremy Bartos, Ryan Dellinger
  • METHOD FOR TREATING NON-MELANOMA SKIN CANCER BY INDUCING UDP-GLUCURONOSYLTRANSFERASE ACTIVITY USING PTEROSTILBENE
    Publication number: 20150011650
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CHROMADEX INC.
    Inventors: Jeremy Bartos, Ryan Dellinger
  • Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
    Patent number: 8841350
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: September 23, 2014
    Assignees: ChromaDex Inc., The Regents of the University of California
    Inventors: Jeremy Bartos, Ryan Dellinger
  • PTEROSTILBENE AND CURCUMIN COMBINATION FOR TREATMENT OF OXIDATIVE STRESS AND INFLAMMATION
    Publication number: 20130296440
    Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 30, 2013
    Publication date: November 7, 2013
    Applicant: ChromaDex Inc.
    Inventor: Jeremy Bartos
  • PTEROSTILBENE AND STATIN COMBINATION FOR TREATMENT OF METABOLIC DISEASE, CARDIOVASCULAR DISEASE, AND INFLAMMATION
    Publication number: 20130072509
    Abstract: A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to neurodegenerative diseases. A method of lowering lipid levels in an individual is also provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable carrier, wherein lipid levels are decreased.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: ChromaDex Inc.
    Inventor: Jeremy Bartos
  • METHOD FOR INDUCING UDP-GLUCURONOSYLTRANSFERASE ACTIVITY USING PTEROSTILBENE
    Publication number: 20120289605
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Application
    Filed: May 8, 2012
    Publication date: November 15, 2012
    Applicants: The Regents of the University of California, ChromaDex Inc.
    Inventors: Jeremy Bartos, Ryan Dellinger